True Wealth Design’s Standard BioTools LAB Stock Holding History

True Wealth Design’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$292	Sell	354 -1,220	-78%	-$1.15K	﹤0.01%	2363
2026 Q1	$1.45K	Sell	1,574 -371	-19%	-$449	﹤0.01%	1671
2025 Q4	$2.49K	Sell	1,945 -341	-15%	-$458	﹤0.01%	1369
2025 Q3	$2.97K	Hold	2,286	–	–	﹤0.01%	1312
2025 Q2	$2.74K	Buy	2,286 +1,190	+109%	+$1.32K	﹤0.01%	1043
2025 Q1	$1.18K	Buy	+1,096	New	+$1.54K	﹤0.01%	1206

Other funds holding LAB

MAM

Marquette Asset Management Minneapolis, Minnesota $779M AUM 23.4% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

True Wealth Design's LAB Position: Q2 2026 in Review

True Wealth Design reduced its Standard BioTools (LAB) stake by 78% in Q2 2026, selling an estimated $1.15K and leaving 354 shares worth $292. The position accounts for ﹤0.01% of the portfolio, ranked #2363.

True Wealth Design first reported a position in LAB in Q1 2025 and has held it in 6 quarters since. The position peaked at $2.97K in Q3 2025. 5 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

True Wealth Design held 354 shares of Standard BioTools worth $292 as of Q2 2026.
True Wealth Design sold 1,220 Standard BioTools shares in Q2 2026, an estimated $1.15K.
Standard BioTools made up ﹤0.01% of True Wealth Design's portfolio in Q2 2026, its #2363 holding.
True Wealth Design first reported a position in Standard BioTools in Q1 2025 and has held it in 6 quarters since.
True Wealth Design's Standard BioTools position peaked at $2.97K in Q3 2025.
5 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.